Home・Akcijų sąrašas・Johnson and Johnson

Johnson and Johnson

Uždarymo kaina

SektoriusSveikatos priežiūra

256.7 0.2

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

255.22

Max

261.27

Pagrindiniai rodikliai
By Trading Economics
Pajamos	299M 5.5B
Pardavimai	1.2B 25B
P/E Sektoriaus vid.	29.548 68.51
Pelnas, tenkantis vienai akcijai	2.9
Dividendų pajamingumas	2.04
Pelno marža	21.865
Darbuotojai	138,200
EBITDA	-1.1B 7.2B

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+9.35% upside

Dividendai
By Acuity
Dividendų pajamingumas Sektoriaus vid.	2.04% 2.29%
Kitas uždarbis	2026-10-13
Kitas dividendų mokėjimo data	2026-09-08
Kita Ex Dividend data	2026-08-25

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-5.5B 613B
Ankstesnė atidarymo kaina	256.5
Ankstesnė uždarymo kaina	256.7

Naujienos nuotaikos

By Acuity

30%

70%

97 / 340 reitingas Healthcare

Johnson and Johnson Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-06 23:06; UTC

Johnson & Johnson shares are higher in after-market hours, following a session within its one-month trading range. No specific news was identified for the move.

2026-08-05 23:51; UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance within their one-month trading range amid broader cautious market sentiment.

2026-08-04 23:06; UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance and stability amid broader market conditions.

2026-08-03 23:06; UTC

Johnson & Johnson shares are higher in after-market trading, supported by stronger-than-expected manufacturing PMI data for July that signals sector growth.

2026-08-01 00:01; UTC

Johnson & Johnson shares gained in after-market trading, reflecting a cumulative return of 0.35% since Friday's close, despite no specific news driving the movement.

2026-07-31 23:01; UTC

Johnson & Johnson shares are higher in after-market trading, showing notable strength amid mixed performance in U.S. markets with no specific news identified.

2026-07-30 18:22; UTC

News

Event

Johnson & Johnson shares are lower amid concerns over a $1 billion acquisition of Firefly Bio and a partnership with Sail Biomedicines, impacting future earnings.

2026-07-29 21:41; UTC

News

Johnson & Johnson lowered its fiscal year 2026 adjusted EPS guidance to $10.86 to $11.01, contributing to a decline in after-market trading.

2026-07-28 23:31; UTC

Johnson & Johnson shares are higher in after-market trading, remaining above their 20-day moving average after six consecutive daily gains.

2026-07-27 23:31; UTC

News

Social Media

Johnson & Johnson shares are higher in after-market trading following a proposed $5.5 billion settlement for ovarian talc litigation involving about 76,000 claims.

2026-07-24 23:26; UTC

Johnson & Johnson shares declined in after-market trading, continuing a downward trend since Friday's close, despite the broader market's stability amid bond market concerns.

2026-07-23 10:06; UTC

Event

Johnson & Johnson's OTTAVA™ Robotic Surgical System received FDA authorization. Shares are lower in pre-market trading amid broader market declines.

2026-07-22 23:36; UTC

Event

Johnson & Johnson shares are higher in after-market trading following FDA authorization of the OTTAVA™ Robotic Surgical System, the first table-integrated soft tissue robotic system.

2026-07-21 23:11; UTC

Shares of Johnson & Johnson are higher in after-market trading, with no specific news identified. The stock remains below its 20-day moving average.

2026-07-20 19:26; UTC

Social Media

News

Johnson & Johnson shares are lower today, continuing a decline since Friday. The company targets $101 billion in revenue amid bearish technical trends.

Akcijų palyginimas

Kainos pokytis

Johnson and Johnson Prognozė

Kainos tikslas

By TipRanks

9.35% į viršų

12 mėnesių prognozė

Vidutinis 281 USD 9.35%

Aukščiausias 305 USD

Žemiausias 255 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Johnson and Johnson kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

17 ratings

Pirkti

Laikyti

Parduoti

Remiantis 17 analitikų, pateikusių Johnson and Johnson akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

97 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.